Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib

被引：0
|
作者：
Wu, Yi-Long
Yang, James Chih-Hsin
Park, Keunchil
Xu, Lianzhe
Bladt, Friedhelm
Johne, Andreas
Li, Peiqi
Zheng, Hongxia
Massimini, Giorgio
机构：
[1] GGH, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[5] Merck Serono Pharmaceut R&D Co Ltd, Global Biostat, Beijing, Peoples R China
[6] Merck KGaA, Translat Innovat Platform Oncol, Global Res & Dev, Darmstadt, Germany
[7] Merck KGaA, Clin Pharmacol, Darmstadt, Germany
[8] Merck Serono Pharmaceut R&D Co Ltd, Global Clin Dev Ctr, Beijing, Peoples R China
[9] EMD Serono, Global Res & Early Dev, Boston, MA USA
[10] Merck KGaA, Global Res & Early Dev, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8121
引用
收藏
页数：1
相关论文
共 50 条
  • [31] NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation
    Inoue, Akira
    Hosomi, Yukio
    Maemondo, Makoto
    Sugawara, Shunichi
    Kato, Terufumi
    Takahashi, Kazuhlsa
    Fujita, Yuka
    Gamma, Aklhlko
    Harada, Toshiyuki
    Oizumi, Satoshi
    Minato, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
    Xing, Ligang
    Wu, Gang
    Wang, Luhua
    Li, Jiancheng
    Wang, Jianhua
    Yuan, Zhiyong
    Chen, Ming
    Xu, Yaping
    Fu, Xiaolong
    Zhu, Zhengfei
    Lu, You
    Han, Chun
    Xia, Tingyi
    Xie, Conghua
    Li, Guang
    Ma, Shenglin
    Lu, Bing
    Lin, Qin
    Zhu, Guangying
    Qu, Baolin
    Zhu, Wanqi
    Yu, Jinming
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (05): : 1349 - 1358
  • [33] Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan
    Ohe, Y.
    Ichinose, Y.
    Nishiwaki, Y.
    Yamamoto, N.
    Negoro, S.
    Duffield, E.
    Jiang, H.
    Saijo, N.
    Mok, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
    Rimawi, Mothaffar
    Ferrero, Jean-Marc
    de la Haba-Rodriguez, Juan
    Poole, Christopher
    De Placido, Sabino
    Osborne, C. Kent
    Hegg, Roberto
    Easton, Valerie
    Wohlfarth, Christine
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2826 - +
  • [35] Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
    Lu, Shun
    Dong, Xiaorong
    Jian, Hong
    Chen, Jianhua
    Chen, Gongyan
    Sun, Yuping
    Ji, Yinghua
    Wang, Ziping
    Shi, Jianhua
    Lu, Junguo
    Chen, Shaoshui
    Zhang, Guojun
    Lv, Dongqing
    Liu, Chunling
    Li, Juan
    Yu, Xinmin
    Lin, Zhong
    Yu, Zhuang
    Wang, Zhehai
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)
    Yang, J.
    Cheng, Y.
    Murakami, H.
    Yang, P-C.
    He, J.
    Nakagawa, K.
    Kang, J. H.
    Kim, J-H.
    Hozak, R.
    Nguyen, T.
    Wang, X.
    Enatsu, S.
    Puri, T.
    Orlando, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib-LUX-Lung 5 (LL5).
    Schuler, Martin H.
    Yang, Chih-Hsin
    Park, Keunchil
    Bennouna, Jaafar
    Chen, Yuh-Min
    Chouaid, Christos
    De Marinis, Filippo
    Feng, Ji Feng
    Grossi, Francesco
    Kim, Dong-Wan
    Liu, Xiaoqing
    Lu, Shun
    Strausz, Janos
    Vinnyk, Yurii
    Wiewrodt, Rainer
    Zhou, Caicun
    Chand, Vikram K.
    Wang, Bushi
    Kim, Joo-Hang
    Planchard, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
    Spicer, J.
    Provencio, M.
    Garrido Lopez, P.
    Bosch-Barrera, J.
    de Castro Carpeno, F. J.
    Felip, E.
    Trigo, J.
    Viteri, S.
    Coart, E.
    Schmidt, E.
    Christiansen, A. V.
    Zocca, M-B.
    Andersen, M. H.
    Ehrnrooth, E.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    He, Yong
    Li, Li
    Jiang, Liyan
    Wang, Yubo
    Zhao, Yizhuo
    Zhang, Xiaoju
    Wu, Guoming
    Zhou, Xiangdong
    Sun, Jianguo
    Bai, Jun
    Ren, Biyong
    Tian, Kun
    Xu, Zhi
    Xiao, Hualiang
    Zhou, Qi
    Han, Rui
    Chen, Hengyi
    Wang, Haidong
    Yang, Zhenzhou
    Gao, Chan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
12345